Analysts set AUD 4.47 target for 4DMedical stock

Published on 10/24/2026 at 18:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2026 revenue rose 21.00 percent to AUD 7.10 million. 4DMedical stock costs EUR 2.37 on October 24, 2026 at 1:04 p.m. CEST.

Analyst target and revenue growth

Analysts cited an AUD 4.47 average target for 4DMedical stock on October 23, 2026.
Fiscal 2026 operating revenue rose 21.00 percent to AUD 7.10 million.
4DMedical stock costs EUR 2.37 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
The company ended fiscal 2026 with AUD 278.00 million in cash.

4Dmedical, AU0000095416, Illustration mit AI erstellt.

4DMedical stock (ISIN AU0000095416) has an AUD 4.47 average analyst target after a reported increase from AUD 4.13. On October 23, 2026, Simply Wall St reported the target change, based on three analysts. The AUD 4.47 target is 21.80 percent above the ASX price of AUD 3.67 on October 23, 2026.

4DMedical stock was trading at EUR 2.37 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST. The euro quotation provides the clearest live reference for investors in Germany, while the company's primary listing remains in Australia.

Revenue growth meets wider adoption

Fiscal 2026 operating revenue rose 21.00 percent to AUD 7.10 million, according to the company's 2026 annual report published on September 24, 2026. FinancialFilings reported that the company delivered its software products at 540 sites at June 30, 2026, up 39.00 percent from the prior year.

The operating expansion was visible in usage as well. 4DMedical produced 344,075 scans in fiscal 2026, up 77.00 percent from fiscal 2025, while gross margin reached 93.00 percent. The figures point to rising deployment and utilization, although the revenue base remains small relative to the company's valuation.

Cash supports the commercial push

The annual report placed cash at AUD 278.00 million on June 30, 2026. A separate October 21, 2026 company profile by The Capital Network said 4DMedical's software products were operating at 540 sites and that fiscal 2026 scans reached 344,075.

The same company profile described CT:VQ as a non-contrast ventilation-perfusion imaging product and said the technology had reached commercial use across leading US medical centers. It also reported a three-year agreement with SimonMed Imaging and an expanded distribution agreement with Philips.

Upcoming shareholder date

4DMedical's annual general meeting is scheduled for October 28, 2026. The date gives investors the next formal checkpoint for management commentary on commercial adoption, cash deployment and the path from site growth to revenue.

Price and operating context

The company's ASX quotation was AUD 3.67 at the close of October 23, 2026, with a market capitalization of AUD 2.2 billion and volume of 2,202,691 shares. Its 52-week range was AUD 1.40 to AUD 7.55 on that date, leaving the share price 51.39 percent below the high.

4DMedical combines respiratory imaging software with a growing installed base. The key investor question is whether the 21.00 percent revenue increase and 77.00 percent scan growth can scale fast enough to support the valuation reflected in the AUD 4.47 target.

The further course of trading is shown by the continuously updated real-time quote of 4DMedical stock.